Quanterix (NASDAQ: QTRX) is one of 185 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare Quanterix to similar businesses based on the strength of its earnings, profitability, valuation, analyst recommendations, institutional ownership, risk and dividends.
This table compares Quanterix and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings for Quanterix and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Quanterix presently has a consensus target price of $26.50, indicating a potential upside of 38.89%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.45%. Given Quanterix’s stronger consensus rating and higher possible upside, equities analysts clearly believe Quanterix is more favorable than its rivals.
Institutional & Insider Ownership
49.7% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 14.5% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Quanterix and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Quanterix Competitors||$217.40 million||-$39.57 million||-17.33|
Quanterix’s rivals have higher revenue, but lower earnings than Quanterix. Quanterix is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Quanterix beats its rivals on 7 of the 11 factors compared.
Quanterix Company Profile
Quanterix Corporation is a United States-based company, which is a developer of tools in high definition diagnostics. The Company offers single molecule array (Simoa) platform, whcich uses single molecule measurements to access proteins. Simoa focuses on research and clinical testing applications. The Company focuses on research and diagnostics for brain injuries, heart disease, cancer and other diseases with its technology. The Company offers Simoa HD-1 analyzer, which creates high density arrays of approximately 40 femtoliter microwells. Its Simoa HD-1 analyzer is an automated immunoassay platform with multiplexing and custom assay capability. The Company offers Simoa consumables, which include Simoa Discs, Simoa Cuvettes, Simoa Sealing Oil, Simoa Buffers and Disposable Tips. It offers a range of complete assay kits, including multiplex panels, covering a range of therapeutic areas.Its services include Simoa Accelerator Lab and custom assay development services.
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.